BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, Elshourbagy NA, Ellis CE, Middlemiss DN, Brown F. Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol 1999;128:1-3. [PMID: 10498827 DOI: 10.1038/sj.bjp.0702780] [Cited by in Crossref: 140] [Cited by in F6Publishing: 133] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Al-Barazanji KA, Wilson S, Baker J, Jessop DS, Harbuz MS. Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats. J Neuroendocrinol 2001;13:421-4. [PMID: 11328451 DOI: 10.1046/j.1365-2826.2001.00655.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 4.4] [Reference Citation Analysis]
2 Duffet L, Kosar S, Panniello M, Viberti B, Bracey E, Zych AD, Radoux-Mergault A, Zhou X, Dernic J, Ravotto L, Tsai YC, Figueiredo M, Tyagarajan SK, Weber B, Stoeber M, Gogolla N, Schmidt MH, Adamantidis AR, Fellin T, Burdakov D, Patriarchi T. A genetically encoded sensor for in vivo imaging of orexin neuropeptides. Nat Methods 2022;19:231-41. [PMID: 35145320 DOI: 10.1038/s41592-021-01390-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
3 Burdakov D, Liss B, Ashcroft FM. Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium--calcium exchanger. J Neurosci 2003;23:4951-7. [PMID: 12832517 [PMID: 12832517 DOI: 10.1523/jneurosci.23-12-04951.2003] [Cited by in Crossref: 113] [Article Influence: 5.9] [Reference Citation Analysis]
4 Cai J, Cooke FE, Sherborne BS. Antagonists of the orexin receptors. Expert Opinion on Therapeutic Patents 2006;16:631-46. [DOI: 10.1517/13543776.16.5.631] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
5 Akbari E, Naghdi N, Motamedi F. The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides 2007;28:650-6. [PMID: 17161886 DOI: 10.1016/j.peptides.2006.11.002] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
6 Liu J, Han J, Izawa K, Sato T, White S, Meanwell NA, Soloshonok VA. Cyclic tailor-made amino acids in the design of modern pharmaceuticals. Eur J Med Chem 2020;208:112736. [PMID: 32966895 DOI: 10.1016/j.ejmech.2020.112736] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
7 Soffin EM, Evans ML, Gill CH, Harries MH, Benham CD, Davies CH. SB-334867-A antagonises orexin mediated excitation in the locus coeruleus. Neuropharmacology 2002;42:127-33. [PMID: 11750922 DOI: 10.1016/s0028-3908(01)00156-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
8 Kushikata T, Hirota K, Yoshida H, Kudo M, Lambert DG, Smart D, Jerman JC, Matsuki A. Orexinergic neurons and barbiturate anesthesia. Neuroscience 2003;121:855-63. [PMID: 14580935 DOI: 10.1016/s0306-4522(03)00554-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
9 Morales A, Bonnet C, Bourgoin N, Touvier T, Nadam J, Laglaine A, Navarro F, Moulin C, Georges B, Pequignot JM, Bezin L. Unexpected expression of orexin-B in basal conditions and increased levels in the adult rat hippocampus during pilocarpine-induced epileptogenesis. Brain Res 2006;1109:164-75. [PMID: 16904080 DOI: 10.1016/j.brainres.2006.06.075] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
10 Liu L, Wang Q, Liu A, Lan X, Huang Y, Zhao Z, Jie H, Chen J, Zhao Y. Physiological Implications of Orexins/Hypocretins on Energy Metabolism and Adipose Tissue Development. ACS Omega 2020;5:547-55. [PMID: 31956801 DOI: 10.1021/acsomega.9b03106] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
11 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
12 Nair SG, Golden SA, Shaham Y. Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats. Br J Pharmacol 2008;154:406-16. [PMID: 18223663 DOI: 10.1038/bjp.2008.3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 105] [Article Influence: 7.2] [Reference Citation Analysis]
13 Taheri S, Bloom S. Orexins/hypocretins: waking up the scientific world: Orexins and hypocretins. Clinical Endocrinology 2001;54:421-9. [DOI: 10.1046/j.1365-2265.2001.01247.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
14 Burlet S, Tyler CJ, Leonard CS. Direct and indirect excitation of laterodorsal tegmental neurons by Hypocretin/Orexin peptides: implications for wakefulness and narcolepsy. J Neurosci 2002;22:2862-72. [PMID: 11923451 DOI: 20026234] [Cited by in Crossref: 184] [Article Influence: 9.2] [Reference Citation Analysis]
15 Smart D, Jerman JC, Brough SJ, Neville WA, Jewitt F, Porter RA. The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors. Br J Pharmacol 2000;129:1289-91. [PMID: 10742282 DOI: 10.1038/sj.bjp.0703257] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wang P, Wang M, Zhang L, Zhong S, Jiang W, Wang Z, Sun C, Zhang S, Liu Z. Functional characterization of an orexin neuropeptide in amphioxus reveals an ancient origin of orexin/orexin receptor system in chordate. Sci China Life Sci 2019;62:1655-69. [PMID: 30945108 DOI: 10.1007/s11427-018-9421-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Ishii Y, Blundell JE, Halford JC, Upton N, Porter R, Johns A, Rodgers RJ. Satiety enhancement by selective orexin-1 receptor antagonist SB-334867: influence of test context and profile comparison with CCK-8S. Behav Brain Res 2005;160:11-24. [PMID: 15836896 DOI: 10.1016/j.bbr.2004.11.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
18 İzgüt-uysal VN, Gemici B, Tan R. Effect of orexin-A on phagocytic activity of peritoneal macrophage in starved rats. Cellular Immunology 2011;271:85-8. [DOI: 10.1016/j.cellimm.2011.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 Aracri P, Banfi D, Pasini ME, Amadeo A, Becchetti A. Hypocretin (orexin) regulates glutamate input to fast-spiking interneurons in layer V of the Fr2 region of the murine prefrontal cortex. Cereb Cortex 2015;25:1330-47. [PMID: 24297328 DOI: 10.1093/cercor/bht326] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
20 Hervieu G, Cluderay J, Harrison D, Roberts J, Leslie R. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 2001;103:777-97. [DOI: 10.1016/s0306-4522(01)00033-1] [Cited by in Crossref: 340] [Cited by in F6Publishing: 109] [Article Influence: 16.2] [Reference Citation Analysis]
21 Holmqvist T, Akerman KE, Kukkonen JP. Orexin signaling in recombinant neuron-like cells. FEBS Lett 2002;526:11-4. [PMID: 12208495 DOI: 10.1016/s0014-5793(02)03101-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
22 Nixon JP, Kotz CM, Novak CM, Billington CJ, Teske JA. Neuropeptides controlling energy balance: orexins and neuromedins. Handb Exp Pharmacol 2012;:77-109. [PMID: 22249811 DOI: 10.1007/978-3-642-24716-3_4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
23 Holland P, Goadsby PJ. The Hypothalamic Orexinergic System: Pain and Primary Headaches. Headache: The Journal of Head and Face Pain 2007;47:951-62. [DOI: 10.1111/j.1526-4610.2007.00842.x] [Cited by in Crossref: 128] [Cited by in F6Publishing: 105] [Article Influence: 8.5] [Reference Citation Analysis]
24 Smart D, Haynes AC, Williams G, Arch JR. Orexins and the treatment of obesity. Eur J Pharmacol 2002;440:199-212. [PMID: 12007536 DOI: 10.1016/s0014-2999(02)01429-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
25 Nixon J, Smale L. Individual differences in wheel-running rhythms are related to temporal and spatial patterns of activation of orexin A and B cells in a diurnal rodent (arvicanthis niloticus). Neuroscience 2004;127:25-34. [DOI: 10.1016/j.neuroscience.2004.04.052] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
26 Wigglesworth M, Lawless K, Standing D, Mackenzie E, Kitchen V, Mckay F, Ward E, Brough S, Stylianou M, Jewitt F, Mclaren-douglas A, Jowet M, Tamayama N, Finnigan D, Ding J, Wise A. Use of Cryopreserved Cells for Enabling Greater Flexibility in Compound Profiling. J Biomol Screen 2008;13:354-62. [DOI: 10.1177/1087057108317768] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
27 Suzuki R, Shimojima H, Funahashi H, Nakajo S, Yamada S, Guan JL, Tsurugano S, Uehara K, Takeyama Y, Kikuyama S, Shioda S. Orexin-1 receptor immunoreactivity in chemically identified target neurons in the rat hypothalamus. Neurosci Lett 2002;324:5-8. [PMID: 11983281 DOI: 10.1016/s0304-3940(02)00140-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
28 Shu Q, Hu ZL, Huang C, Yu XW, Fan H, Yang JW, Fang P, Ni L, Chen JG, Wang F. Orexin-A promotes cell migration in cultured rat astrocytes via Ca2+-dependent PKCα and ERK1/2 signals. PLoS One 2014;9:e95259. [PMID: 24748172 DOI: 10.1371/journal.pone.0095259] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
29 Zhang JY, Nawoschik S, Kowal D, Smith D, Spangler T, Ochalski R, Schechter L, Dunlop J. Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. European Journal of Pharmacology 2003;472:33-8. [DOI: 10.1016/s0014-2999(03)01855-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
30 Kohlmeier KA, Inoue T, Leonard CS. Hypocretin/orexin peptide signaling in the ascending arousal system: elevation of intracellular calcium in the mouse dorsal raphe and laterodorsal tegmentum. J Neurophysiol. 2004;92:221-235. [PMID: 14999052 DOI: 10.1152/jn.00076.2004] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 3.9] [Reference Citation Analysis]
31 Fonseca EM, Dias MB, Bícego KC, Gargaglioni LH. Orexin in the toad Rhinella schneideri: The location of orexinergic neurons and the role of orexin in ventilatory responses to hypercarbia and hypoxia. Respir Physiol Neurobiol 2016;224:90-9. [PMID: 25434286 DOI: 10.1016/j.resp.2014.11.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
32 Kane J, Parker S, Li M. Hypothalamic orexin-A binding sites are downregulated by chronic nicotine treatment in the rat. Neuroscience Letters 2001;298:1-4. [DOI: 10.1016/s0304-3940(00)01730-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
33 España RA, Baldo BA, Kelley AE, Berridge CW. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience 2001;106:699-715. [PMID: 11682157 DOI: 10.1016/s0306-4522(01)00319-0] [Cited by in Crossref: 218] [Cited by in F6Publishing: 95] [Article Influence: 10.9] [Reference Citation Analysis]
34 Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity--a review. Neuropeptides 2006;40:375-401. [PMID: 16935329 DOI: 10.1016/j.npep.2006.07.001] [Cited by in Crossref: 285] [Cited by in F6Publishing: 250] [Article Influence: 17.8] [Reference Citation Analysis]
35 Higa Y, Kashiwadani H, Sugimura M, Kuwaki T. Orexinergic descending inhibitory pathway mediates linalool odor-induced analgesia in mice. Sci Rep 2021;11:9224. [PMID: 33927235 DOI: 10.1038/s41598-021-88359-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Dun NJ, Le Dun, S, Chen C, Hwang LL, Kwok EH, Chang J. Orexins: a role in medullary sympathetic outflow. Regulatory Peptides 2000;96:65-70. [DOI: 10.1016/s0167-0115(00)00202-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
37 Nunn C, Cervia D, Langenegger D, Tenaillon L, Bouhelal R, Hoyer D. Comparison of functional profiles at human recombinant somatostatin sst2 receptor: simultaneous determination of intracellular Ca2+ and luciferase expression in CHO-K1 cells. Br J Pharmacol 2004;142:150-60. [PMID: 15037513 DOI: 10.1038/sj.bjp.0705735] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
38 Kukkonen JP. Lipid signaling cascades of orexin/hypocretin receptors. Biochimie 2014;96:158-65. [PMID: 23810911 DOI: 10.1016/j.biochi.2013.06.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
39 Nixon JP, Smale L. A comparative analysis of the distribution of immunoreactive orexin A and B in the brains of nocturnal and diurnal rodents. Behav Brain Funct 2007;3:28. [PMID: 17567902 DOI: 10.1186/1744-9081-3-28] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 5.9] [Reference Citation Analysis]
40 Zhang Y, Kowal D, Kramer A, Dunlop J. Evaluation of FLIPR Calcium 3 Assay Kit—A New No-Wash Fluorescence Calcium Indicator Reagent. J Biomol Screen 2003;8:571-7. [DOI: 10.1177/1087057103257240] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
41 Pekala D, Blasiak T, Raastad M, Lewandowski MH. The influence of orexins on the firing rate and pattern of rat intergeniculate leaflet neurons - electrophysiological and immunohistological studies: Influence of orexins on intergeniculate leaflet. European Journal of Neuroscience 2011;34:1406-18. [DOI: 10.1111/j.1460-9568.2011.07868.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
42 Kane JK, Tanaka H, Parker SL, Yanagisawa M, Li MD. Sensitivity of orexin-A binding to phospholipase C inhibitors, neuropeptide Y, and secretin. Biochem Biophys Res Commun 2000;272:959-65. [PMID: 10860858 DOI: 10.1006/bbrc.2000.2880] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
43 Cluderay JE, Harrison DC, Hervieu GJ. Protein distribution of the orexin-2 receptor in the rat central nervous system. Regul Pept 2002;104:131-44. [PMID: 11830288 DOI: 10.1016/s0167-0115(01)00357-3] [Cited by in Crossref: 198] [Cited by in F6Publishing: 65] [Article Influence: 9.9] [Reference Citation Analysis]
44 Bülbül M, Tan R, Gemici B, Özdem S, Üstünel İ, Acar N, İzgüt-uysal VN. Endogenous orexin-A modulates gastric motility by peripheral mechanisms in rats. Peptides 2010;31:1099-108. [DOI: 10.1016/j.peptides.2010.03.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
45 Nair SG, Adams-Deutsch T, Epstein DH, Shaham Y. The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking.Prog Neurobiol. 2009;89:18-45. [PMID: 19497349 DOI: 10.1016/j.pneurobio.2009.05.003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 6.4] [Reference Citation Analysis]
46 Hirota K, Kushikata T, Kudo M, Kudo T, Lambert DG, Matsuki A. Orexin A and B evoke noradrenaline release from rat cerebrocortical slices. Br J Pharmacol 2001;134:1461-6. [PMID: 11724752 DOI: 10.1038/sj.bjp.0704409] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
47 Porter RA, Chan WN, Coulton S, Johns A, Hadley MS, Widdowson K, Jerman JC, Brough SJ, Coldwell M, Smart D, Jewitt F, Jeffrey P, Austin N. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorganic & Medicinal Chemistry Letters 2001;11:1907-10. [DOI: 10.1016/s0960-894x(01)00343-2] [Cited by in Crossref: 117] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
48 Kukkonen JP, Holmqvist T, Ammoun S, Åkerman KEO. Functions of the orexinergic/hypocretinergic system. American Journal of Physiology-Cell Physiology 2002;283:C1567-91. [DOI: 10.1152/ajpcell.00055.2002] [Cited by in Crossref: 200] [Cited by in F6Publishing: 188] [Article Influence: 10.0] [Reference Citation Analysis]
49 Rodgers RJ, Wright FL, Snow NF, Taylor LJ. Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plus-maze-naïve or plus-maze-experienced mice. Behav Brain Res 2013;243:213-9. [PMID: 23333844 DOI: 10.1016/j.bbr.2012.12.064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
50 Kukkonen JP. OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells. Cell Signal 2016;28:51-60. [PMID: 26582739 DOI: 10.1016/j.cellsig.2015.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
51 Lang M, Bufe B, De Pol S, Reiser O, Meyerhof W, Beck-sickinger AG. Structural properties of orexins for activation of their receptors. J Peptide Sci 2006;12:258-66. [DOI: 10.1002/psc.716] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
52 Wang B, You ZB, Wise RA. Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network. Biol Psychiatry 2009;65:857-62. [PMID: 19251246 DOI: 10.1016/j.biopsych.2009.01.018] [Cited by in Crossref: 87] [Cited by in F6Publishing: 94] [Article Influence: 6.7] [Reference Citation Analysis]
53 Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, Kamenecka TM, Borgland SL, Kenny PJ, Carlezon WA. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proceedings of the National Academy of Sciences 2014;111:E1648-55. [DOI: 10.1073/pnas.1315542111] [Cited by in Crossref: 159] [Cited by in F6Publishing: 145] [Article Influence: 19.9] [Reference Citation Analysis]
54 Ward RJ, Pediani JD, Milligan G. Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging. Br J Pharmacol 2011;162:1439-52. [PMID: 21175569 DOI: 10.1111/j.1476-5381.2010.01156.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
55 Rasmussen K, Hsu MA, Yang Y. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. Neuropsychopharmacology 2007;32:786-92. [PMID: 17063151 DOI: 10.1038/sj.npp.1301239] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
56 Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG. Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev. 2006;58:46-57. [PMID: 16507882 DOI: 10.1124/pr.58.1.4] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 7.0] [Reference Citation Analysis]
57 Xia J, Chen X, Cheng S, Hu Z. Mechanisms of orexin A-evoked changes of intracellular calcium in primary cultured cortical neurons: . NeuroReport 2005;16:783-6. [DOI: 10.1097/00001756-200505120-00025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
58 Bengtsson MW, Mäkelä K, Herzig K, Flemström G. Short food deprivation inhibits orexin receptor 1 expression and orexin-A induced intracellular calcium signaling in acutely isolated duodenal enterocytes. American Journal of Physiology-Gastrointestinal and Liver Physiology 2009;296:G651-8. [DOI: 10.1152/ajpgi.90387.2008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
59 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
60 Kourosh-arami M, Javan M, Semnanian S. Inhibition of orexin receptor 1 contributes to the development of morphine dependence via attenuation of cAMP response element-binding protein and phospholipase Cβ3. Journal of Chemical Neuroanatomy 2020;108:101801. [DOI: 10.1016/j.jchemneu.2020.101801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 Celik O, Aydin S, Celik N, Yilmaz M. Peptides: Basic determinants of reproductive functions. Peptides 2015;72:34-43. [DOI: 10.1016/j.peptides.2015.05.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
62 Imperatore R, Cristino L. Role of Orexin-B/Orexin 2 receptor in myocardial protection. Clinical Science 2019;133:853-7. [DOI: 10.1042/cs20181036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Chen H, Yang L, Chen F, Yan J, Yang N, Wang YJ, Zhu ZR, Hu ZA, Sui JF, Hu B. Functional inactivation of orexin 1 receptors in the cerebellum disrupts trace eyeblink conditioning and local theta oscillations in guinea pigs. Behav Brain Res 2013;250:114-22. [PMID: 23680162 DOI: 10.1016/j.bbr.2013.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
64 Chen X, Chen L, Du Y. Orexin-A increases the firing activity of hippocampal CA1 neurons through orexin-1 receptors: Orexin-A in Hippocampal CA1 Neurons. Journal of Neuroscience Research 2017;95:1415-26. [DOI: 10.1002/jnr.23975] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
65 Imperatore R, Palomba L, Cristino L. Role of Orexin-A in Hypertension and Obesity. Curr Hypertens Rep 2017;19. [DOI: 10.1007/s11906-017-0729-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
66 Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004;141:340-6. [PMID: 14691055 DOI: 10.1038/sj.bjp.0705610] [Cited by in Crossref: 110] [Cited by in F6Publishing: 94] [Article Influence: 5.8] [Reference Citation Analysis]
67 Yu L, Zhang XY, Zhang J, Zhu JN, Wang JJ. Orexins excite neurons of the rat cerebellar nucleus interpositus via orexin 2 receptors in vitro. Cerebellum 2010;9:88-95. [PMID: 19921532 DOI: 10.1007/s12311-009-0146-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
68 Holmqvist T, Åkerman KE, Kukkonen JP. High specificity of human orexin receptors for orexins over neuropeptide Y and other neuropeptides. Neuroscience Letters 2001;305:177-80. [DOI: 10.1016/s0304-3940(01)01839-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
69 Rodgers R, Ishii Y, Halford J, Blundell J. Orexins and appetite regulation. Neuropeptides 2002;36:303-25. [DOI: 10.1016/s0143-4179(02)00085-9] [Cited by in Crossref: 118] [Cited by in F6Publishing: 27] [Article Influence: 5.9] [Reference Citation Analysis]
70 Teske JA, Billington CJ, Kotz CM. Hypocretin/orexin and energy expenditure. Acta Physiol (Oxf) 2010;198:303-12. [PMID: 20070282 DOI: 10.1111/j.1748-1716.2010.02075.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
71 White JR, Lee JM, Dede K, Imburgia CS, Jurewicz AJ, Chan G, Fornwald JA, Dhanak D, Christmann LT, Darcy MG, Widdowson KL, Foley JJ, Schmidt DB, Sarau HM. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J Biol Chem 2000;275:36626-31. [PMID: 10969084 DOI: 10.1074/jbc.M006613200] [Cited by in Crossref: 84] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
72 Calu DJ, Chen YW, Kawa AB, Nair SG, Shaham Y. The use of the reinstatement model to study relapse to palatable food seeking during dieting. Neuropharmacology 2014;76 Pt B:395-406. [PMID: 23660229 DOI: 10.1016/j.neuropharm.2013.04.030] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
73 Lang M, Söll RM, Dürrenberger F, Dautzenberg FM, Beck-sickinger AG. Structure−Activity Studies of Orexin A and Orexin B at the Human Orexin 1 and Orexin 2 Receptors Led to Orexin 2 Receptor Selective and Orexin 1 Receptor Preferring Ligands. J Med Chem 2004;47:1153-60. [DOI: 10.1021/jm030982t] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
74 Darker JG, Porter RA, Eggleston DS, Smart D, Brough SJ, Sabido-david C, Jerman JC. Structure–activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorganic & Medicinal Chemistry Letters 2001;11:737-40. [DOI: 10.1016/s0960-894x(01)00043-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
75 Vogel HG, Vogel WH, Schölkens BA, Sandow J, Müller G, Vogel WF. Anti-obesity activity1. In: Vogel HG, Vogel WH, Schölkens BA, Sandow J, Müller G, Vogel WF, editors. Drug Discovery and Evaluation. Berlin: Springer Berlin Heidelberg; 2002. pp. 1053-92. [DOI: 10.1007/3-540-29837-1_13] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Kaplan GB, Lakis GA, Zhoba H. Sleep-Wake and Arousal Dysfunctions in Post-Traumatic Stress Disorder:Role of Orexin Systems. Brain Res Bull 2022:S0361-9230(22)00121-6. [PMID: 35618150 DOI: 10.1016/j.brainresbull.2022.05.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Reynen PH, Martin GR, Eglen RM, MacLennan SJ. Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors. Br J Pharmacol 2000;129:1339-46. [PMID: 10742289 DOI: 10.1038/sj.bjp.0703184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
78 McGregor R, Thannickal TC, Siegel JM. Pleasure, addiction, and hypocretin (orexin). Handb Clin Neurol 2021;180:359-74. [PMID: 34225941 DOI: 10.1016/B978-0-12-820107-7.00022-7] [Reference Citation Analysis]
79 Ericson MD, Haskell-Luevano C. A Review of Single-Nucleotide Polymorphisms in Orexigenic Neuropeptides Targeting G Protein-Coupled Receptors. ACS Chem Neurosci 2018;9:1235-46. [PMID: 29714060 DOI: 10.1021/acschemneuro.8b00151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
80 Haynes AC, Chapman H, Taylor C, Moore GB, Cawthorne MA, Tadayyon M, Clapham JC, Arch JR. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regulatory Peptides 2002;104:153-9. [DOI: 10.1016/s0167-0115(01)00358-5] [Cited by in Crossref: 97] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
81 Valiante S, Liguori G, Tafuri S, Campese R, Monaco R, Paino S, Laforgia V, Staiano N, Vittoria A. Expression of orexin A and its receptor 1 in the human prostate. J Anat 2013;222:473-80. [PMID: 23425077 DOI: 10.1111/joa.12030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
82 Matzeu A, Martin-fardon R. Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value. Front Behav Neurosci 2022;15:787595. [DOI: 10.3389/fnbeh.2021.787595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, Jerman JC. SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol 2001;132:1179-82. [PMID: 11250867 DOI: 10.1038/sj.bjp.0703953] [Cited by in Crossref: 223] [Cited by in F6Publishing: 226] [Article Influence: 10.6] [Reference Citation Analysis]
84 Evans NA, Groarke DA, Warrack J, Greenwood CJ, Dodgson K, Milligan G, Wilson S. Visualizing differences in ligand-induced β-arrestin-GFP interactions and trafficking between three recently characterized G protein-coupled receptors: Differential receptor trafficking of β-arrestin 1. Journal of Neurochemistry 2001;77:476-85. [DOI: 10.1046/j.1471-4159.2001.00269.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 2.6] [Reference Citation Analysis]
85 Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M, Akerman KE, Kukkonen JP. Distinct recognition of OX1 and OX2 receptors by orexin peptides. J Pharmacol Exp Ther. 2003;305:507-514. [PMID: 12606634 DOI: 10.1124/jpet.102.048025] [Cited by in Crossref: 126] [Cited by in F6Publishing: 120] [Article Influence: 6.6] [Reference Citation Analysis]
86 Ishii Y, Blundell JE, Halford JC, Upton N, Porter R, Johns A, Rodgers RJ. Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol Behav. 2004;81:129-140. [PMID: 15059692 DOI: 10.1016/j.physbeh.2004.01.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
87 Coleman P, de Lecea L, Gotter A, Hagan J, Hoyer D, Kilduff T, Kukkonen JP, Porter R, Renger J, Siegel JM, Sutcliffe G, Upton N, Winrow CJ. Orexin receptors in GtoPdb v.2021.3. IUPHAR BPS Guide Pharm CITE 2021;2021. [PMID: 34927075 DOI: 10.2218/gtopdb/f51/2021.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Shahid IZ, Rahman AA, Pilowsky PM. Orexin and Central Regulation of Cardiorespiratory System. Sleep Hormones. Elsevier; 2012. pp. 159-84. [DOI: 10.1016/b978-0-12-394623-2.00009-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
89 Shakeri-Nejad K, Hoch M, Hoever P, Dingemanse J. Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist. Eur J Pharm Sci 2013;49:836-44. [PMID: 23770377 DOI: 10.1016/j.ejps.2013.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
90 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
91 Putula J, Pihlajamaa T, Kukkonen JP. Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery. Br J Pharmacol 2014;171:5816-28. [PMID: 25132134 DOI: 10.1111/bph.12883] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
92 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
93 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
94 Thorpe AJ, Teske JA, Kotz CM. Orexin A-induced feeding is augmented by caloric challenge. Am J Physiol Regul Integr Comp Physiol. 2005;289:R367-R372. [PMID: 15947069 DOI: 10.1152/ajpregu.00737.2004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
95 Grabauskas G, Moises HC. Gastrointestinal-projecting neurones in the dorsal motor nucleus of the vagus exhibit direct and viscerotopically organized sensitivity to orexin. J Physiol. 2003;549:37-56. [PMID: 12679367 DOI: 10.1113/jphysiol.2002.029546] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
96 Akbari E, Motamedi F, Naghdi N, Noorbakhshnia M. The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task. Behav Brain Res 2008;187:172-7. [PMID: 17977608 DOI: 10.1016/j.bbr.2007.09.019] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 4.0] [Reference Citation Analysis]
97 Kotani A, Ikeda H, Koshikawa N, Cools AR. Role of orexin receptors in the nucleus accumbens in dopamine-dependent turning behaviour of rats. Neuropharmacology 2008;54:613-9. [PMID: 18160080 DOI: 10.1016/j.neuropharm.2007.11.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
98 Nakamura Y, Miura S, Yoshida T, Kim J, Sasaki K. Cytosolic calcium elevation induced by orexin/hypocretin in granule cell domain cells of the rat cochlear nucleus in vitro. Peptides 2010;31:1579-88. [PMID: 20457199 DOI: 10.1016/j.peptides.2010.04.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
99 Arch J. Orexins, feeding and the big picture. Br J Nutr 2000;84:401-3. [DOI: 10.1017/s0007114500001707] [Cited by in Crossref: 16] [Article Influence: 1.1] [Reference Citation Analysis]
100 Bernard R, Lydic R, Baghdoyan HA. Hypocretin (orexin) receptor subtypes differentially enhance acetylcholine release and activate g protein subtypes in rat pontine reticular formation. J Pharmacol Exp Ther 2006;317:163-71. [PMID: 16352704 DOI: 10.1124/jpet.105.097071] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
101 Kukkonen JP, Akerman KE. Orexin receptors couple to Ca2+ channels different from store-operated Ca2+ channels. Neuroreport 2001;12:2017-20. [PMID: 11435939 DOI: 10.1097/00001756-200107030-00046] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.1] [Reference Citation Analysis]
102 Milasta S, Evans NA, Ormiston L, Wilson S, Lefkowitz RJ, Milligan G. The sustainability of interactions between the orexin-1 receptor and beta-arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. Biochem J 2005;387:573-84. [PMID: 15683363 DOI: 10.1042/BJ20041745] [Cited by in Crossref: 58] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
103 Guo Y, Feng P. OX2R activation induces PKC-mediated ERK and CREB phosphorylation. Exp Cell Res 2012;318:2004-13. [PMID: 22652455 DOI: 10.1016/j.yexcr.2012.04.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
104 Chen XW, Mu Y, Huang HP, Guo N, Zhang B, Fan SY, Xiong JX, Wang SR, Xiong W, Huang W, Liu T, Zheng LH, Zhang CX, Li LH, Yu ZP, Hu ZA, Zhou Z. Hypocretin-1 potentiates NMDA receptor-mediated somatodendritic secretion from locus ceruleus neurons. J Neurosci 2008;28:3202-8. [PMID: 18354023 DOI: 10.1523/JNEUROSCI.4426-07.2008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
105 Larsson KP, Akerman KE, Magga J, Uotila S, Kukkonen JP, Näsman J, Herzig KH. The STC-1 cells express functional orexin-A receptors coupled to CCK release. Biochem Biophys Res Commun 2003;309:209-16. [PMID: 12943684 DOI: 10.1016/s0006-291x(03)01563-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
106 Xia JX, Fan SY, Yan J, Chen F, Li Y, Yu ZP, Hu ZA. Orexin A-induced extracellular calcium influx in prefrontal cortex neurons involves L-type calcium channels. J Physiol Biochem 2009;65:125-36. [PMID: 19886391 DOI: 10.1007/BF03179063] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
107 Zhan S, Cai GQ, Zheng A, Wang Y, Jia J, Fang H, Yang Y, Hu M, Ding Q. Tumor necrosis factor-alpha regulates the Hypocretin system via mRNA degradation and ubiquitination. Biochim Biophys Acta 2011;1812:565-71. [PMID: 21094253 DOI: 10.1016/j.bbadis.2010.11.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
108 Maton WM, Stazi F, Manzo AM, Pachera R, Ribecai A, Stabile P, Perboni A, Giubellina N, Bravo F, Castoldi D, Provera S, Turco L, Bryant S, Westerduin P, Profeta R, Nalin A, Miserazzi E, Spada S, Mingardi A, Mattioli M, Andreotti D. An Efficient Scalable Route for the Synthesis of Enantiomerically Pure tert -Butyl-(1 R ,4 S ,6 R )-4-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate. Org Process Res Dev 2010;14:1239-47. [DOI: 10.1021/op100164v] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
109 Magga J, Bart G, Oker-Blom C, Kukkonen JP, Akerman KE, Näsman J. Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1. Biochem Pharmacol 2006;71:827-36. [PMID: 16430869 DOI: 10.1016/j.bcp.2005.12.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
110 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
111 Wang W, Richerson GB. Changes in glucose do not alter baseline firing rate or chemosensitivity of serotonin neurons cultured from the medullary raphé. Respir Physiol Neurobiol 2007;157:235-41. [PMID: 17336599 DOI: 10.1016/j.resp.2007.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Näsman J, Bart G, Larsson K, Louhivuori L, Peltonen H, Akerman KE. The orexin OX1 receptor regulates Ca2+ entry via diacylglycerol-activated channels in differentiated neuroblastoma cells. J Neurosci 2006;26:10658-66. [PMID: 17050705 DOI: 10.1523/JNEUROSCI.2609-06.2006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
113 Turunen PM, Jäntti MH, Kukkonen JP. OX1 orexin/hypocretin receptor signaling through arachidonic acid and endocannabinoid release. Mol Pharmacol 2012;82:156-67. [PMID: 22550093 DOI: 10.1124/mol.112.078063] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
114 Larsson KP, Peltonen HM, Bart G, Louhivuori LM, Penttonen A, Antikainen M, Kukkonen JP, Akerman KE. Orexin-A-induced Ca2+ entry: evidence for involvement of trpc channels and protein kinase C regulation. J Biol Chem 2005;280:1771-81. [PMID: 15537648 DOI: 10.1074/jbc.M406073200] [Cited by in Crossref: 55] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
115 Yin H, Pattrick N, Zhang X, Klauke N, Cordingley HC, Haswell SJ, Cooper JM. Quantitative comparison between microfluidic and microtiter plate formats for cell-based assays. Anal Chem 2008;80:179-85. [PMID: 18052343 DOI: 10.1021/ac701958z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
116 Skrzypski M, Billert M, Nowak KW, Strowski MZ. The role of orexin in controlling the activity of the adipo-pancreatic axis. J Endocrinol 2018;238:R95-R108. [PMID: 29848609 DOI: 10.1530/JOE-18-0122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
117 Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001;21:9273-9. [PMID: 11717361 [PMID: 11717361 DOI: 10.1523/jneurosci.21-23-09273.2001] [Cited by in Crossref: 348] [Article Influence: 17.4] [Reference Citation Analysis]
118 Gorojankina T, Grébert D, Salesse R, Tanfin Z, Caillol M. Study of orexins signal transduction pathways in rat olfactory mucosa and in olfactory sensory neurons-derived cell line Odora: multiple orexin signalling pathways. Regul Pept 2007;141:73-85. [PMID: 17292491 DOI: 10.1016/j.regpep.2006.12.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
119 Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M, Laboisse C, Laburthe M, Voisin T. Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis. J Biol Chem 2004;279:45875-86. [PMID: 15310763 DOI: 10.1074/jbc.M404136200] [Cited by in Crossref: 73] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
120 Kokare DM, Patole AM, Carta A, Chopde CT, Subhedar NK. GABAA receptors mediate orexin-A induced stimulation of food intake. Neuropharmacology 2006;50:16-24. [DOI: 10.1016/j.neuropharm.2005.07.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
121 Liu F, Weng SJ, Yang XL, Zhong YM. Orexin-A potentiates L-type calcium/barium currents in rat retinal ganglion cells. Neuroscience 2015;305:225-37. [PMID: 26259903 DOI: 10.1016/j.neuroscience.2015.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
122 Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 2014;171:314-31. [PMID: 23902572 DOI: 10.1111/bph.12324] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 13.0] [Reference Citation Analysis]
123 Rodgers RJ, Halford JCG, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JRS, Upton N, Porter RA, Johns A, Blundell JE. SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats: Orexin-1 receptors and feeding patterns. European Journal of Neuroscience 2001;13:1444-52. [DOI: 10.1046/j.0953-816x.2001.01518.x] [Cited by in Crossref: 174] [Cited by in F6Publishing: 169] [Article Influence: 8.3] [Reference Citation Analysis]
124 Zhang XY, Yu L, Zhuang QX, Zhu JN, Wang JJ. Central functions of the orexinergic system. Neurosci Bull 2013;29:355-65. [PMID: 23299718 DOI: 10.1007/s12264-012-1297-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
125 Johnston PA, Johnston PA. Cellular platforms for HTS: three case studies. Drug Discovery Today 2002;7:353-63. [DOI: 10.1016/s1359-6446(01)02140-7] [Cited by in Crossref: 99] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
126 Akbari E, Motamedi F, Davoodi FG, Noorbakhshnia M, Ghanbarian E. Orexin-1 receptor mediates long-term potentiation in the dentate gyrus area of freely moving rats. Behav Brain Res 2011;216:375-80. [PMID: 20728473 DOI: 10.1016/j.bbr.2010.08.017] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
127 Wieland HA, Söll RM, Doods HN, Stenkamp D, Hurnaus R, Lämmle B, Beck-Sickinger AG. The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin 1-type receptor. Eur J Biochem. 2002;269:1128-1135. [PMID: 11856342 DOI: 10.1046/j.0014-2956.2001.02739.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
128 Peltonen HM, Åkerman KE, Bart G. A role for PKD1 and PKD3 activation in modulation of calcium oscillations induced by orexin receptor 1 stimulation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2010;1803:1206-12. [DOI: 10.1016/j.bbamcr.2010.07.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
129 Smart D, Jerman JC. The physiology and pharmacology of the orexins. Pharmacology & Therapeutics 2002;94:51-61. [DOI: 10.1016/s0163-7258(02)00171-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
130 Kohlmeier KA, Tyler CJ, Kalogiannis M, Ishibashi M, Kristensen MP, Gumenchuk I, Chemelli RM, Kisanuki YY, Yanagisawa M, Leonard CS. Differential actions of orexin receptors in brainstem cholinergic and monoaminergic neurons revealed by receptor knockouts: implications for orexinergic signaling in arousal and narcolepsy. Front Neurosci 2013;7:246. [PMID: 24391530 DOI: 10.3389/fnins.2013.00246] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
131 Imperatore R, Palomba L, Morello G, Spiezio AD, Piscitelli F, Marzo VD, Cristino L. Formation of OX-1R/CB 1 R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. Pharmacological Research 2016;111:600-9. [DOI: 10.1016/j.phrs.2016.07.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
132 Sutcliffe JG, de Lecea L. The hypocretins: Setting the arousal threshold. Nat Rev Neurosci 2002;3:339-48. [DOI: 10.1038/nrn808] [Cited by in Crossref: 310] [Cited by in F6Publishing: 293] [Article Influence: 15.5] [Reference Citation Analysis]
133 Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000;12:726-30. [PMID: 10712652 DOI: 10.1046/j.1460-9568.2000.00919.x] [Cited by in Crossref: 256] [Cited by in F6Publishing: 240] [Article Influence: 11.6] [Reference Citation Analysis]
134 Hwang LL, Chen CT, Dun NJ. Mechanisms of orexin-induced depolarizations in rat dorsal motor nucleus of vagus neurones in vitro. J Physiol 2001;537:511-20. [PMID: 11731582 DOI: 10.1111/j.1469-7793.2001.00511.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 3.2] [Reference Citation Analysis]
135 Emmerzaal T, Doelen RV, Roubos E, Kozicz T. Orexinergic innervation of urocortin1 and cocaine and amphetamine regulated transcript neurons in the midbrain centrally projecting Edinger–Westphal nucleus. Journal of Chemical Neuroanatomy 2013;54:34-41. [DOI: 10.1016/j.jchemneu.2013.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
136 Holmqvist T, Johansson L, Ostman M, Ammoun S, Akerman KE, Kukkonen JP. OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. J Biol Chem 2005;280:6570-9. [PMID: 15611118 DOI: 10.1074/jbc.M407397200] [Cited by in Crossref: 89] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
137 Upton N. In Vivo Pharmacology of Orexin (Hypocretin) Receptors. In: de Lecea L, Sutcliffe JG, editors. Hypocretins. Boston: Springer US; 2005. pp. 205-20. [DOI: 10.1007/0-387-25446-3_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
138 Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol 2014;171:294-313. [PMID: 23848055 DOI: 10.1111/bph.12296] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]